5mg vial · Lyophilized powder
Dual GLP-1 / GIP agonist — engineered single molecule activating both incretin pathways for stronger metabolic signal than GLP-1-only agonists.
Relative emphasis across the research domains this compound is most studied for.
Sourced direct from a vetted GMP-aligned manufacturer. No re-labels, no middle layers.
View brandDetailed compound information
Tirzepatide is a dual agonist at both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — a single molecule engineered to activate two incretin pathways simultaneously. The GLP-1 component delivers appetite suppression and gastric motility effects; the GIP component adds a parallel metabolic route via adipocyte-receptor activation, improving insulin sensitivity and fatty-acid metabolism independent of GLP-1 signaling.
Continue exploring
Reference material & peer-reviewed citations
Research peptides are chemical reagents for laboratory analysis. Regulations vary by jurisdiction — it is the buyer's responsibility to ensure compliance with local laws. See our Terms & Conditions page for the full regulatory framework across the EU, UK, US, Switzerland, Thailand, and other major markets.
Lyophilized (unreconstituted) peptides should be stored at -20°C for long-term storage or 2-8°C (refrigerated) for short-term use. Once reconstituted with bacteriostatic water, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles — aliquot into smaller portions if needed.
For laboratory research use only. Not for human consumption, diagnosis, treatment, prevention, or in-vivo administration. By purchasing you confirm you are a qualified researcher or institution.
Reconstitute the 5mg vial with 2mL bacteriostatic water along the interior wall. Swirl gently — do not shake. Yields 2.5 mg/mL. On a U-100 insulin syringe, 10 IU = 0.1 mL = 250 mcg; titrate weekly per protocol. Subcutaneous abdomen or thigh, rotating sites. Half-life ~5 days — once-weekly dosing.
Gently inject bacteriostatic water (bacteriostatic water) along the inside wall of the vial — do not spray directly onto the powder. Let it dissolve naturally or gently swirl. Never shake vigorously. Standard reconstitution: add the desired volume of bacteriostatic water based on your concentration needs. For example, 5mg peptide + 2.5ml bacteriostatic water = 2mg/ml concentration.
Yes. Every batch undergoes independent third-party HPLC (High-Performance Liquid Chromatography) and mass spectrometry analysis. We provide a Certificate of Analysis (COA) for each product, verifying identity, purity (≥99%), and the absence of contaminants. COA documents are available for download on each product page.
Yes. We offer temperature-controlled shipping to most EU and Asian countries. Standard EU delivery is 24-48 hours. International orders are shipped in discreet, professional packaging with cold-chain protection where required. Customs documentation and regulatory paperwork are provided as needed.
We currently operate on an inquiry-based ordering system. Submit your order through checkout and our team will contact you within 24 hours to confirm details and arrange payment. We are working on integrating direct payment options for a seamless experience.
A Physician's Endorsement
Quality assurance isn't a marketing claim — it's a daily decision. I choose LifeSpanSupply because every batch is independently HPLC-verified to 99% purity, fully traceable, and held to the safety standards my patients deserve.
Dr. Pichaya Sangaunmu
M.D. · Wellness · Beauty · Longevity
Three curated paths into the research literature on this compound.
## Mechanism Tirzepatide is a dual agonist at both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — a sing.
Comprehensive research hub on GLP-1 receptor agonists — Semaglutide, Tirzepatide, Retatrutide. Mechanism, trial data, head-to-head.
Selected peer-reviewed publications on this research compound, resolvable via DOI to the publisher of record.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine.
doi.org/10.1056/NEJMoa2206038Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine.
doi.org/10.1056/NEJMoa2107519Coskun T, Sloop KW, Loghin C, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism.
doi.org/10.1016/j.molmet.2018.09.009Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA.
doi.org/10.1001/jama.2023.24945Citations are provided for research reference only and do not constitute medical advice. Reagents are sold strictly for laboratory use; consult primary sources for full study design, dosing, and limitations.
